The targeted therapy Perjeta (chemical name: pertuzumab), when used in combination with the targeted therapy Herceptin (chemical name: trastuzumab) and the chemotherapy Taxotere (chemical name: docetaxel) before breast cancer surgery, has been shown to improve survival in women diagnosed with high-risk, early-stage HER2-positive breast cancer.
Perjeta, also in combination with Herceptin and Taxotere, also has been shown to improve survival in women diagnosed with HER2-positive metastatic breast cancer. Metastatic breast cancer is cancer that has spread away from the breast to another part of the body, such as the bones or liver.
So doctors wondered if adding Perjeta to the standard treatment of Herceptin and chemotherapy after surgery could offer more benefits to women diagnosed with early-stage, HER2-positive breast cancer. Doctors call treatments given after surgery “adjuvant” treatments.
Early results from a study suggest that adding Perjeta to Herceptin and chemotherapy after surgery to treat early-stage, HER2-positive breast cancer slightly improves survival; women diagnosed with high-risk, HER2-positive, early-stage disease got more benefits.
The research was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2017 and published online on June 5, 2017 by The New England Journal of Medicine:
- Read the ASCO Annual Meeting abstract of “APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).”
- Read The New England Journal of Medicine abstract of “Adjuvant Pertuzumab and Trastuzumab in Early HE…
Full credit to the source URL for this article; please feel free to follow the link through to the full article.
Leave a Comment
You must be logged in to post a comment.